A comprehensive view of Eli Lilly & Co.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Eli Lilly dumps Innovent Biologic's Tyvyt PD-1 inhibitor after FDA rebuff, nixing high-profile Chinese cancer drug

FDA withdraws emergency use authorization of Eli Lilly’s bebtelovimab injectable COVID-19 antibody therapy, citing the therapy is most likely ineffective against Omicron BQ.1 and BQ.1.1; Lilly had supplied 60,000 doses of the drug to US government in Q3

Lilly completes acquisition of Akouos, expanding its efforts to help people with genetic diseases; acquisition includes Akouos's portfolio of adeno-associated viral gene therapies to treat inner ear conditions, including sensorineural hearing loss

INTERNATIONAL PATENT: ELI LILLY AND COMPANY FILES APPLICATION FOR "MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS"

INTERNATIONAL PATENT: ELI LILLY AND COMPANY FILES APPLICATION FOR "COMPOUNDS AND METHODS TARGETING EPIREGULIN"

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count